Stressgen infectious news

SSB again restructured and said it will reduce its headcount by 33% to 27 from 40 to save cash. In May, SSB cut headcount by 49% and deferred all R&D activities not related to its HspE7 program (see BioCentury, May 2). The compound, a fusion protein of heat shock protein (Hsp) 65 and E7 human papillomavirus (HPV) antigen, has completed a Phase III trial to treat anal dysplasia and Phase II trials to treat genital warts, cervical dysplasia and recurrent respiratory papillomatosis (RRP). ...